Skip to main content
Fig. 5 | BMC Urology

Fig. 5

From: Health-related quality of life in the randomized phase 3 study of ramucirumab plus docetaxel versus placebo plus docetaxel in platinum-refractory advanced urothelial carcinoma (RANGE)

Fig. 5

Proportion of patients with improvement in global QoL (a) and pain (b) scales among those patients with BOR of CR/PR or SD. BOR best overall response, CR complete response, DOC docetaxel, n number of patients, PL placebo, PR partial response, QoL quality of life; RAM ramucirumab, SD stable disease. For each scale at each postbaseline assessment, proportion of patients with improved or stable scores between treatment and placebo arms was compared using the Fisher’s exact test. PR/CR as BOR: RAM + DOC (n = 68) and PL + DOC (n = 37). SD as BOR: RAM + DOC (n = 104) and PL + DOC (n = 110)

Back to article page